Skip to content
value.today
NeuroPace, Inc. logo

NeuroPace, Inc.

NPCE
$487 Mmarket cap on Sep 18, 2026+68.1% since Jan 2024
Compare
World rank
#12,666
Revenue
$100 M
For year ending December-2025
Net income
$-21 M
-21.5% margin
SEC filing
Employees
209
As of December 31, 2025
SEC filing

NeuroPace, Inc. in brief

NeuroPace, Inc. is a listed company in the Medical Devices industry, based in Mountain View, California, USA. It was founded in 1997. Its market value was $487 M on 18 September 2026, which makes it the 12,666th largest listed company in the world and the 2,552nd largest in the USA on this site. In the year to December 2025 it had sales of $100 M and a net loss of $21 M. It employs about 209 people and Joel Becker is its chief executive. Its shares trade under the symbol NPCE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About NeuroPace, Inc.

We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By continuously monitoring and analyzing the brain’s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, our RNS System is programmed by clinicians to deliver the precise amount of therapy when and where it is needed and provides exceptional clinical outcomes with approximately three minutes of stimulation on average per day. Our RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care. We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment. As of December 31, 2025, over 8,000 patients have received our RNS System. We believe our compelling body of long-term clinical data, demonstrating continuous improvement in outcomes over time, will support the continued adoption of our RNS System among the approximately 575,000 adults in the United States with drug-resistant focal epilepsy. We continue seeking indication expansion to, over time, cover the entire approximately 1.2 million drug-resistant epilepsy patients in the United States and may additionally seek to expand our operations to reach the approximately 16.5 million drug-resistant epilepsy patients globally.

From the company's annual report filed with the US SEC: read the report

NeuroPace, Inc. timeline

4 events, 1997–2025
  1. 1997
  2. 🏁
    · approximate
    Founded
  3. 2011
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 23 April 2021; shares registered for exchange trading on 14 April 2021.
  7. 2025
  8. 💰
    Record revenue of $100 million
    FY2025, the highest of the 6 years on record.

Events of NeuroPace, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$137 M$274 M$411 M$548 M2023202420252026

World rank over time

▲ up 5,156 places since 2022
2022-01-07: #17911#17,91120222022-12-25: #27074#27,07420222023-07-30: #21490#21,49020232024-01-05: #15971#15,97120242026-03-08: #7192#7,19220262026-08-01: #12211#12,21120262026-09-18: #12755#12,7552026

Rank in USA: #3,664 (Jan 2022) · #5,023 (Dec 2022) · #4,195 (Jul 2023) · #2,962 (Jan 2024) · #1,267 (Mar 2026) · #2,532 (Aug 2026) · #2,547 (Sep 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
4.8×
Price / book
25.6×
Free cash flow yield
-2.3%
Net margin (TTM)
-18.4%
Operating margin
-16.3%
Return on equity
-99.4%
Liabilities / assets
82.0%
Net debt
$37M
Revenue growth
+25.1%
R&D / revenue
27.9%
Revenue per employee
$478 K
Profit per employee
$-103 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $41M, net income $-24M$41MFY20Fiscal year ending Dec 2021: revenue $45M, net income $-36M$45MFY21Fiscal year ending Dec 2022: revenue $46M, net income $-47M$46MFY22Fiscal year ending Dec 2023: revenue $65M, net income $-33M$65MFY23Fiscal year ending Dec 2024: revenue $80M, net income $-27M$80MFY24Fiscal year ending Dec 2025: revenue $100M, net income $-21M$100MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$100M+25.1%$-16M$-21M-21.5%
Dec 2024$80M+22.1%$-22M$-27M-34.0%
Dec 2023$65M+43.7%$-27M$-33M-50.4%
Dec 2022$46M+0.8%$-41M$-47M-103.4%
Dec 2021$45M+9.8%$-24M$-36M-79.9%
Dec 2020$41M—$-13M$-24M-59.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M$0M$-11M$-0.66$0.00
Dec 2024$-18M$0M$-18M$-0.93$0.00
Dec 2023$-20M$0M$-20M$-1.27$0.00
Dec 2022$-37M$1M$-37M$-1.91—
Dec 2021$-25M$0M$-25M$-2.17—
Dec 2020$-22M$0M$-22M$-117.85—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$103M
Net income, trailing 12 months
$-19M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $21M, net income $-5M$21MDec ’24Three months to Mar 2025: revenue $23M, net income $-7M$23MMar ’25Three months to Jun 2025: revenue $20M, net income $-9M$20MJun ’25Three months to Sep 2025: revenue $23M, net income $-4M$23MSep ’25Three months to Dec 2025 (from the annual report): revenue $35M, net income $-3M$35MDec ’25Three months to Mar 2026: revenue $22M, net income $-7M$22MMar ’26Three months to Jun 2026: revenue $23M, net income $-6M$23MJun ’26Three months to Sep 2026: revenue $23M, net income $-3M$23MSep ’26

Latest quarter to Sep 2026: revenue $23M (-1.1% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of NeuroPace, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$100 M
Operating income
$-16 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$106 M
Total liabilities
$87 M
Total equity
$19 M

As of December-2025

Top 100 institutional investors in NeuroPace, Inc.#

As of Sep 30, 2026
105 institutions held 26.8 M shares (about 77.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 60.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in NeuroPace, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1First Light Asset Management, LLC3,983,577+1,122,410 (+39.23%)11.56%$55 MNov 16, 2026
2Polar Capital Holdings Plc3,298,1040 (0.00%)9.57%$45 MNov 16, 2026
3Soleus Capital Management, L.P.3,218,000+306,878 (+10.54%)9.34%$44 MNov 16, 2026
4Morgan Stanley2,568,872-85,519 (-3.22%)7.46%$35 MNov 13, 2026
5BlackRock, Inc.2,467,499-10,104 (-0.41%)7.16%$34 MNov 13, 2026
6Driehaus Capital Management LLC1,429,439-17,952 (-1.24%)4.15%$20 MNov 16, 2026
7Vanguard Capital Management LLC1,234,175+7,103 (+0.58%)3.58%$17 MNov 13, 2026
8Orbimed Advisors LLC1,055,125-450,000 (-29.90%)3.06%$15 MNov 16, 2026
9Deutsche Bank AG\935,652-3,267 (-0.35%)2.72%$13 MNov 6, 2026
10Armistice Capital, LLC800,000+108,000 (+15.61%)2.32%$11 MNov 16, 2026
11Geode Capital Management, LLC662,187-4,113 (-0.62%)1.92%$9 MNov 6, 2026
12State Street Corp566,654+16,522 (+3.00%)1.64%$8 MNov 12, 2026
13Silvercrest Asset Management Group LLC314,454-29,670 (-8.62%)0.91%$4 MNov 16, 2026
14Qube Research & Technologies Ltd303,591+82,354 (+37.22%)0.88%$4 MNov 13, 2026
15D. E. Shaw & Co., Inc.263,276+102,195 (+63.44%)0.76%$4 MNov 16, 2026
16Northern Trust Corp259,039-986 (-0.38%)0.75%$4 MNov 16, 2026
17Citadel Advisors LLC247,158+118,358 (+91.89%)0.72%$3 MNov 16, 2026
18Vanguard Portfolio Management LLC223,522+3,151 (+1.43%)0.65%$3 MNov 13, 2026
19Essex Investment Management Co LLC202,202-6,501 (-3.11%)0.59%$3 MOct 19, 2026
20Vanguard Fiduciary Trust Co192,471+9,937 (+5.44%)0.56%$3 MNov 13, 2026
21Bank Of America Corp /de/179,981+159,732 (+788.84%)0.52%$2 MNov 16, 2026
22Palumbo Wealth Management LLC167,945-41,254 (-19.72%)0.49%$2 MNov 13, 2026
23Algert Global LLC164,516-20,258 (-10.96%)0.48%$2 MNov 17, 2026
24HighMark Wealth Management LLC163,0000 (0.00%)0.47%$2 MNov 17, 2026
25Jpmorgan Chase & Co154,231-19,080 (-11.01%)0.45%$2 MNov 12, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in NeuroPace, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Tudor Investment Corp Et Al143,233+33,359 (+30.36%)0.42%$2 MNov 16, 2026
27Goldman Sachs Group Inc139,600-9,966 (-6.66%)0.41%$2 MNov 16, 2026
28Lazard Asset Management LLC126,251-1,477 (-1.16%)0.37%$2 MNov 16, 2026
29Nuveen, LLC113,647+14,149 (+14.22%)0.33%$2 MNov 10, 2026
30BNP Paribas Financial Markets86,705-972 (-1.11%)0.25%$1 MNov 12, 2026
31Charles Schwab Investment Management Inc77,879+48 (+0.06%)0.23%$1 MNov 16, 2026
32XTX Topco Ltd67,078+46,694 (+229.07%)0.19%$1 MNov 16, 2026
33Legato Capital Management LLC62,633-7,701 (-10.95%)0.18%$1 MNov 10, 2026
34Panagora Asset Management Inc59,974-54,085 (-47.42%)0.17%$1 MNov 12, 2026
35Russell Investments Group, Ltd.59,197-102,967 (-63.50%)0.17%$1 MNov 6, 2026
36Bank of New York Mellon Corp56,501-1,476 (-2.55%)0.16%$1 MNov 5, 2026
37Millennium Management LLC51,078+20,459 (+66.82%)0.15%$1 MNov 16, 2026
38Gsa Capital Partners LLP44,005-71,530 (-61.91%)0.13%$1 MNov 16, 2026
39Renaissance Technologies LLC43,700-67,999 (-60.88%)0.13%$1 MNov 12, 2026
40SEI Investments Co38,667-23,510 (-37.81%)0.11%$1 MNov 10, 2026
41Barclays PLC37,089+6,078 (+19.60%)0.11%$1 MNov 6, 2026
42Rhumbline Advisers32,110+446 (+1.41%)0.09%$0 MNov 10, 2026
43AQR Capital Management LLC31,944-3,976 (-11.07%)0.09%$0 MNov 16, 2026
44Squarepoint Ops LLC31,511+10,246 (+48.18%)0.09%$0 MNov 9, 2026
45Point72 Asset Management, L.P.28,843New0.08%$0 MNov 16, 2026
46State Of Wisconsin Investment Board26,148+10,000 (+61.93%)0.08%$0 MNov 16, 2026
47Polar Asset Management Partners Inc.25,600New0.07%$0 MNov 16, 2026
48Quadrature Capital Ltd24,402New0.07%$0 MNov 13, 2026
49Integrated Quantitative Investments LLC23,413New0.07%$0 MNov 13, 2026
50Western Wealth Management, LLC22,9500 (0.00%)0.07%$0 MNov 9, 2026
51EntryPoint Capital, LLC22,850+6,357 (+38.54%)0.07%$0 MNov 13, 2026
52Price T Rowe Associates Inc /MD/21,7640 (0.00%)0.06%$0 MNov 16, 2026
53UBS Group AG20,320+3,786 (+22.90%)0.06%$0 MNov 10, 2026
54MetLife Investment Management, LLC17,3180 (0.00%)0.05%$0 MNov 16, 2026
55Quantinno Capital Management LP16,834+6,601 (+64.51%)0.05%$0 MNov 13, 2026
56Susquehanna Portfolio Strategies, LLC16,129-6,150 (-27.60%)0.05%$0 MNov 16, 2026
57FMR LLC15,074-539,697 (-97.28%)0.04%$0 MNov 10, 2026
58Two Sigma Investments, LP14,646-15,546 (-51.49%)0.04%$0 MNov 16, 2026
59Jane Street Group, LLC14,271-20,167 (-58.56%)0.04%$0 MNov 12, 2026
60Invesco Ltd.13,907-395 (-2.76%)0.04%$0 MNov 12, 2026
61Alliancebernstein L.P.13,7100 (0.00%)0.04%$0 MNov 16, 2026
62MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.12,670+466 (+3.82%)0.04%$0 MNov 16, 2026
63Wells Fargo & Company/mn11,294-16,123 (-58.81%)0.03%$0 MNov 16, 2026
64Diversified Trust Co11,096New0.03%$0 MNov 6, 2026
65Connor, Clark & Lunn Investment Management Ltd.11,093-17,599 (-61.34%)0.03%$0 MNov 10, 2026
66Entropy Technologies, LP10,616New0.03%$0 MNov 13, 2026
67Vanguard Global Advisers, LLC10,091+115 (+1.15%)0.03%$0 MNov 13, 2026
68Mitsubishi UFJ Asset Management Co., Ltd.9,009-881 (-8.91%)0.03%$0 MNov 5, 2026
69New York State Common Retirement Fund7,7000 (0.00%)0.02%$0 MNov 17, 2026
70Police & Firemen's Retirement System of New Jersey6,123-3,010 (-32.96%)0.02%$0 MNov 9, 2026
71Zurcher Kantonalbank (Zurich Cantonalbank)5,839New0.02%$0 MNov 10, 2026
72UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3,908+3,406 (+678.49%)0.01%$0 MNov 16, 2026
73Employees Retirement System of Texas3,904New0.01%$0 MNov 10, 2026
74Tower Research Capital LLC (TRC)2,815+1,316 (+87.79%)0.01%$0 MNov 16, 2026
75Nisa Investment Advisors, LLC2,778-150 (-5.12%)0.01%$0 MOct 20, 2026
76Legal & General Group Plc2,5860 (0.00%)0.01%$0 MNov 16, 2026
77Ameritas Investment Partners, Inc.2,4550 (0.00%)0.01%$0 MNov 13, 2026
78Royal Bank Of Canada1,963+183 (+10.28%)0.01%$0 MNov 16, 2026
79Citigroup Inc1,315-11,101 (-89.41%)0.00%$0 MNov 4, 2026
80Northwestern Mutual Wealth Management Co1,2000 (0.00%)0.00%$0 MNov 13, 2026
81Sterling Capital Management LLC869+776 (+834.41%)0.00%$0 MOct 22, 2026
82Allworth Financial LP785-722 (-47.91%)0.00%$0 MNov 17, 2026
83Steward Partners Investment Advisory, LLC505+205 (+68.33%)0.00%$0 MNov 13, 2026
84Jones Financial Companies Lllp376+36 (+10.59%)0.00%$0 MNov 13, 2026
85California State Teachers Retirement System3570 (0.00%)0.00%$0 MNov 13, 2026
86Arax Advisory Partners312+190 (+155.74%)0.00%$0 MNov 12, 2026
87SJS Investment Consulting Inc.84+75 (+833.33%)0.00%$0 MOct 26, 2026
88Parallel Advisors, LLC82New0.00%$0 MNov 3, 2026
89US Bancorp \de\74New0.00%$0 MNov 5, 2026
90PNC Financial Services Group, Inc.69+59 (+590.00%)0.00%$0 MNov 6, 2026
91Root Financial Partners, LLC63New0.00%$0 MOct 21, 2026
92Osaic Holdings, Inc.44-87 (-66.41%)0.00%$0 MNov 12, 2026
93Quarry LP39-122 (-75.78%)0.00%$0 MNov 16, 2026
94EverSource Wealth Advisors, LLC27-23 (-46.00%)0.00%$0 MNov 4, 2026
95Rothschild Investment LLC25-3 (-10.71%)0.00%$0 MNov 10, 2026
96SBI Securities Co., Ltd.21-49 (-70.00%)0.00%$0 MOct 22, 2026
97Ascentis Wealth Management, LLC18New0.00%$0 MNov 3, 2026
98Larson Financial Group LLC17-54 (-76.06%)0.00%$0 MNov 5, 2026
99Caitong International Asset Management Co., Ltd15+12 (+400.00%)0.00%$0 MOct 29, 2026
100Simplex Trading, LLC12New0.00%$0 MNov 4, 2026

All 105 institutional investors, with who bought and sold →

Mutual funds holding NeuroPace, Inc.#

93 funds hold shares worth $73 M (about 13.8% of the company). Since their previous reports 47 added shares and 26 sold, buying $1 M net.
Mutual funds holding NeuroPace, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.908,479$14 M2.6%<0.01%+9.8%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors688,652$11 M2.0%0.01%+10%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.290,400$5 M0.84%<0.01%+8.5%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors248,901$4 M0.72%0.03%+19%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC227,093$4 M0.66%0.07%−1.2%May 29, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC288,065$4 M0.84%0.01%+15%Jul 31, 2026
🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC175,099$3 M0.51%0.47%−1.1%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC209,986$3 M0.61%0.03%−42%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.131,045$2 M0.38%0.01%+3.7%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC126,017$2 M0.37%<0.01%−0.8%May 31, 2026
🇺🇸 North Square Dynamic Small Cap FundNorth Square Investments, LLC91,663$2 M0.27%0.19%−3.1%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors89,094$1 M0.26%0.09%+39%Jun 30, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.85,121$1 M0.25%0.17%no changeMay 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC108,032$1 M0.31%0.03%−41%Jul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC58,053$1 M0.17%<0.01%no changeJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.64,471$1 M0.19%0.01%+14%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC49,543$1 M0.14%0.01%+19%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC45,638$1 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC44,216$1 M0.13%0.07%newJun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds42,655$1 M0.12%0.08%−7.0%Jun 30, 2026
🇺🇸 1290 Essex Small Cap Growth FundEquitable Investment Management, LLC50,804$1 M0.15%0.56%no changeJul 31, 2026
🇺🇸 State Street SPDR S&P Health Care Equipment ETFSSGA Funds Management, Inc.39,657$1 M0.12%0.42%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC37,281$1 M0.11%<0.01%+6.5%May 31, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC36,286$1 M0.11%<0.01%+10%May 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.37,644$1 M0.11%0.04%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC29,661$0 M0.09%0.07%−7.8%May 31, 2026
🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC37,056$0 M0.11%0.02%no changeJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC28,700$0 M0.08%0.01%+2.8%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC34,966$0 M0.10%0.01%+12%Jul 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC25,385$0 M0.07%0.04%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC24,269$0 M0.07%<0.01%+29%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC24,832$0 M0.07%0.03%+28%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.23,828$0 M0.07%0.02%+2.3%May 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.19,094$0 M0.06%<0.01%+238%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation17,600$0 M0.05%0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.15,234$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors15,099$0 M0.04%<0.01%−25%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.13,639$0 M0.04%0.01%+11%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.13,081$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.12,112$0 M0.04%0.02%−27%May 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors11,121$0 M0.03%<0.01%−0.7%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.11,062$0 M0.03%0.04%−2.8%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.13,356$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC13,049$0 M0.04%<0.01%+9.8%Jul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC12,674$0 M0.04%0.01%+14%Jul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC10,046$0 M0.03%0.07%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company9,530$0 M0.03%0.01%−0.0%May 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC9,229$0 M0.03%0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.9,100$0 M0.03%<0.01%+11%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC8,141$0 M0.02%0.01%+26%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC8,050$0 M0.02%0.01%+30%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC9,180$0 M0.03%<0.01%+7.4%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC7,285$0 M0.02%0.02%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS6,136$0 M0.02%0.01%+16%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC5,937$0 M0.02%0.04%+30%Jun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC5,907$0 M0.02%0.05%−15%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,770$0 M0.02%<0.01%+38%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC5,770$0 M0.02%<0.01%+38%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC5,684$0 M0.02%0.01%+19%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC4,852$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC5,250$0 M0.02%0.04%—Mar 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.4,167$0 M0.01%0.01%+13%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,997$0 M0.01%0.01%+42%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,999$0 M0.01%0.01%+16%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC3,820$0 M0.01%0.01%+26%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION3,600$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC3,605$0 M0.01%0.01%+30%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC3,696$0 M0.01%0.01%+1.6%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC3,631$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,193$0 M<0.01%0.01%+17%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management2,455$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,016$0 M<0.01%<0.01%+4.0%Jul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC2,986$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC2,413$0 M<0.01%0.03%+28%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC2,091$0 M<0.01%<0.01%+38%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,991$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,985$0 M<0.01%0.01%+24%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,828$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC2,286$0 M<0.01%<0.01%+42%Jul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS2,127$0 M<0.01%0.01%no changeJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,341$0 M<0.01%<0.01%−25%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,198$0 M<0.01%0.01%+8.5%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,033$0 M<0.01%<0.01%+50%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC947$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC937$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 Vanguard Growth And Income FundWellington Management Company LLP800$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC698$0 M<0.01%<0.01%−5.7%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.605$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC585$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC564$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC400$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS317$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC161$0 M<0.01%<0.01%+8.1%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 93 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at NeuroPace, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$302 K
3 purchases, 3 insiders
Sold, 12 months
$399 K
1 sale, 1 insider
Net, 12 months
-$97 K
open market only
Insiders on file
19
since
$302 K-$50.6 M$0Nov 2023: bought $0 (0 trades), sold $213 K (4 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $281 K (5 trades)Jan 2024: bought $0 (0 trades), sold $211 K (4 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $275 K (3 trades)Apr 2024: bought $0 (0 trades), sold $8.2 M (9 trades)AprMay 2024: bought $0 (0 trades), sold $409 K (3 trades)Aug 2024: bought $0 (0 trades), sold $33 K (1 trades)AugSep 2024: bought $0 (0 trades), sold $182 K (10 trades)Oct 2024: bought $0 (0 trades), sold $1.7 M (18 trades)OctJan 2025: bought $0 (0 trades), sold $53 K (3 trades)Feb 2025: bought $0 (0 trades), sold $50.6 M (2 trades)FebMay 2025: bought $0 (0 trades), sold $2.7 M (2 trades)Dec 2025: bought $0 (0 trades), sold $399 K (1 trades)DecNov 2026: bought $302 K (3 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
NeuroPace, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed R. Scott HuennekensDirectorBuyindirect+12,500$8.293$104 K12,500Form 4
filed Joel BeckerCHIEF EXECUTIVE OFFICER, DirectorBuy+11,891$8.350$99 K149,891Form 4
filed Patrick F. WilliamsChief Financial OfficerBuy+11,891$8.338$99 K79,399Form 4
filed Martha MorrellCHIEF MEDICAL OFFICERShares withheld for tax-335$13.97$5 K51,357Form 4
filed Patrick F. WilliamsChief Financial OfficerShares withheld for tax-1,162$14.28$17 K67,508Form 4
filed Joel BeckerCHIEF EXECUTIVE OFFICER, DirectorShares withheld for tax-1,310$14.75$19 K138,000Form 4
filed Martha MorrellCHIEF MEDICAL OFFICERShares withheld for tax-358$14.13$5 K51,692Form 4
filed Joel BeckerCHIEF EXECUTIVE OFFICER, DirectorShares withheld for tax-1,126$14.13$16 K139,310Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: NeuroPace, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
858,343
2.6% of shares · 8.48 days to cover
Dividend per share, Q1 2026
$0.000
— on a year earlier
Buybacks, Q3 2026
$0M
Q3 2026
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-2.6 reverse split ; 1-for-100 reverse split

NeuroPace, Inc. dividends per share by quarter
Dividend, quarterPer share
Q1 2026$0.000
Q1 2025$0.000
NeuroPace, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0M
Q2 2026Q2 2026$0M
Q1 2026Q1 2026$0M
Q4 2025Q4 2025$0M
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$0M
Q1 2025Q1 2025$49.5M
Q4 2024Q4 2025$0M
Q3 2024Q3 2025$0M
Q2 2024Q2 2025$0M
Q1 2024Q1 2025$0M

Fails to deliver

  • : 531 shares at $14.15
  • : 2 shares at $14.74
  • : 28 shares at $14.64
  • : 97 shares at $14.88
  • : 29 shares at $13.70

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

NeuroPace, Inc. scorecard#

Passes 7 of the 18 checks that could be worked out: strongest in growth (5 of 6), weakest in shareholder returns (0 of 3). Fiscal year 2025; market cap of Sep 18, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-09-18, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-09-18, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-09-18, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-09-18, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-09-18, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-09-18, more than 60 days ago.
  • Growth5 of 6
    • ✓Revenue grew in the newest year25.1%Revenue up 25.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years30.0%30.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median30.0%30.0% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.66 vs -0.93Diluted EPS -0.66 in fiscal 2025 against -0.93 the year before (report's currency).
    • ✓Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$24 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-16.3%-16.3% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-158.7%-158.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-16.3%-16.3% in fiscal 2025 against -89.6% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities5.3×Current ratio 5.28 at the end of fiscal 2025.
    • ✗Debt below equity3.1×Debt to equity 3.09 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-2.64Z-score -2.64 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 3
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year12.3%Diluted shares up 12.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-09-18, more than 60 days ago.
    • ✗Free cash flow covers dividends and buybacks-$11 MFree cash flow -$11 M against $50 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from NeuroPace, Inc.'s statements, beside the median of Medical Devices.

NeuroPace, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-16.3%-8.2%
Net margin-21.5%-10.4%
Return on equity-158.7%-16.8%
Revenue growth, 3 years a year30.0%10.8%
Revenue growth25.1%10.4%
Debt to equity3.09×0.64×

5of 9on the Piotroski tests of financial strength

  • Net loss of $21 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$11 million.
  • The share count rose 12.3% in the year.
  • Revenue has grown 5 years in a row.

NeuroPace, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

NeuroPace, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue1008065464541
Cost of revenue232117131211
Gross profit775948323330
Research and development282421221816
Selling, general and administrative—5755513928
Selling and marketing4740————
General and administrative1917————
Operating expenses948175735743
Operating income−16−22−27−41−24−13
Interest and finance income2.83.03.11.60.40.0
Interest expense and finance costs7.58.88.57.57.411
Other non-operating income (expense)−0.50.3−0.3−0.3−5.40.2
Income tax0—————
Net income attributable to shareholders−21−27−33−47−36−24
Earnings per share, basic-0.66-0.93-1.27-1.91-2.17-117.85
Earnings per share, diluted-0.66-0.93-1.27-1.91-2.17-117.85
Shares, weighted average (basic)33292625170.2
Shares, weighted average (diluted)33292625170.2
Dividends per share0.000.000.00———
Balance sheet
Cash and cash equivalents2213186.61926
Short-term investments393948719612
Receivables13r13127.57.18.4
Inventory15r13119.77.86.9
Other current assets1.42.42.73.12.31.2
Current assets9481939813355
Property, plant and equipment1.11.11.01.10.60.5
Right-of-use (leased) assets101213150—
Total assets1069510811413456
Accounts payable1.8r3.02.32.11.40.9
Debt due within a year————02.0
Current liabilities181516119.39.6
Long-term debt596057535051
Lease liabilities (non-current)9.81214150—
Total liabilities878787796062
Retained earnings−552−531−504−471−424−388
Shareholders' equity198.0213574−148
Total liabilities and equity1069510811413456
Shares outstanding34302825240.3
Cash-flow statement
Share-based compensation11109.68.34.31.4
Cash from operating activities−11−18−20−37−25−22
Capital expenditure−0.3−0.3−0.2−0.6−0.4−0.1
Cash from investing activities−0.39.02324−85−11
Debt issued————054
Debt repaid———0−4.1−42
Shares bought back−500————
Cash from financing activities204.38.10.510355
Change in cash8.3−4.611−13−7.423
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What NeuroPace, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

  • Non-US(total)$1 M0.9%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at NeuroPace, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · Agreement ended 1 · New debt 1 · Shareholder vote 3 · Results announced 13

NeuroPace, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Material agreementAgreement endedNew debt8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersResults announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of NeuroPace, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2020$69 MNo. 4$50 to $250 million23equitySEC
Sep 2016$72 MNo. 3$50 to $250 million26equitySEC
Jul 2013$18 MNo. 2$10 to $50 million20equitySEC
Aug 2011$49 MNo. 1$10 to $50 million22equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by NeuroPace, Inc.#

$130 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.

Lobbying, 2025
$130 K
#1,141 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$90 K
  • Medicare/Medicaid3 reports

Lobbying firms hired in 2025

LMH STRATEGIC SOLUTIONS $130 K

NeuroPace, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$90 K—3
2025$130 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “NeuroPace, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at NeuroPace, Inc.#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $91 K a year.

Certified, FY2022
1
#2,031 among companies on value.today
Worker positions
1
Median wage offered
$91 K
a year, full-time
Applications filed
1
NeuroPace, Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Field Clinical EngineerBiomedical Engineers1$91 K

Where: Long Beach, CA 1

NeuroPace, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202211$91 K1
FY202111$155 K1
FY202011$106 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as NeuroPace, Inc.

Discuss NeuroPace, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    NeuroPace, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $23 million (down 1% from a year earlier) and a net loss of $3 million.

  • Mutual funds: 93 funds hold $73 millionautomatic update · Jul 31, 2026

    93 mutual funds in 1 country hold shares of NeuroPace, Inc. worth $73 million, about 13.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 47 funds added shares and 26 sold; on balance they bought $1 million. Share splits are not counted as trading.

How NeuroPace, Inc. compares in Medical Devices

  • Market cap$487 M · higher than 49% of 142
  • Revenue$100 M · higher than 41% of 155
  • Net margin-18.4% · higher than 36% of 144
  • Revenue growth25.1% · higher than 78% of 104
  • Price / sales4.8× · lower than 31% of 96
  • Price / book25.6× · lower than 5% of 99
  • FCF yield-2.3% · higher than 48% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
NeuroPace, Inc.🇺🇸$487 M—-18.4%+25.1%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Sep 18, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at NeuroPace, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show NeuroPace, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about NeuroPace, Inc.? Suggest a correction